Literature DB >> 15161696

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.

Olga Modlich1, Hans-Bernd Prisack, Gerald Pitschke, Uwe Ramp, Rolf Ackermann, Hans Bojar, Thomas A Vögeli, Marc-Oliver Grimm.   

Abstract

PURPOSE: Expression profiling by DNA microarray technology permits the identification of genes underlying clinical heterogeneity of bladder cancer and which might contribute to disease progression, thereby improving assessment of treatment and prediction of patient outcome. EXPERIMENTAL
DESIGN: Invasive (20) and superficial (22) human bladder tumors from 34 patients with known outcome regarding disease recurrence and progression were analyzed by filter-based cDNA arrays (Atlas Human Cancer 1.2; BD Biosciences Clontech) containing 1185 genes. For 9 genes, array data were confirmed using real-time reverse transcription-PCR. Additionally, Atlas array data were validated using Affymetrix GeneChip oligonucleotide arrays with 22,283 human gene fragments and expressed sequence tags sequences in a subset of three superficial and six invasive bladder tumors.
RESULTS: A two-way clustering algorithm using different subsets of gene expression data, including a subset of 41 genes validated by the oligonucleotide array (Affymetrix), classified tumor samples according to clinical outcome as superficial, invasive, or metastasizing. Furthermore, (a) a clonal origin of superficial tumors, (b) highly similar gene expression patterns in different areas of invasive tumors, and (c) an invasive-like pattern was observed in bladder mucosas derived from patients with locally advanced disease. Several gene clusters that characterized invasive or superficial tumors were identified. In superficial bladder tumors, increased mRNA levels of genes encoding transcription factors, molecules involved in protein synthesis and metabolism, and some proteins involved into cell cycle progression and differentiation were observed, whereas transcripts for immune, extracellular matrix, adhesion, peritumoral stroma and muscle tissue components, proliferation, and cell cycle controllers were up-regulated in invasive tumors.
CONCLUSIONS: Gene expression profiling of human bladder cancers provides insight into the biology of bladder cancer progression and identifies patients with distinct clinical phenotypes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161696     DOI: 10.1158/1078-0432.CCR-03-0134

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  31 in total

Review 1.  The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence.

Authors:  Benjamin A Mooso; Ruth L Vinall; Maria Mudryj; Stanley A Yap; Ralph W deVere White; Paramita M Ghosh
Journal:  J Urol       Date:  2014-08-23       Impact factor: 7.450

Review 2.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

3.  [Use of marker systems in the treatment of bladder cancer].

Authors:  M Burger; F Vom Dorp
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

4.  Gene expression is highly correlated on the chromosome level in urinary bladder cancer.

Authors:  George I Lambrou; Maria Adamaki; Dimitris Delakas; Demetrios A Spandidos; Spyros Vlahopoulos; Apostolos Zaravinos
Journal:  Cell Cycle       Date:  2013-05-08       Impact factor: 4.534

5.  Gene expression profiling of chemically induced rat bladder tumors.

Authors:  Ruisheng Yao; Yijun Yi; Clinton J Grubbs; Ronald A Lubet; Ming You
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

Review 6.  Expression profiling for bladder cancer: strategies to uncover prognostic factors.

Authors:  Georg Bartsch; Anirban P Mitra; Richard J Cote
Journal:  Expert Rev Anticancer Ther       Date:  2010-12       Impact factor: 4.512

7.  Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.

Authors:  Jeffrey S Damrauer; Katherine A Hoadley; David D Chism; Cheng Fan; Christopher J Tiganelli; Sara E Wobker; Jen Jen Yeh; Matthew I Milowsky; Gopa Iyer; Joel S Parker; William Y Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

8.  Biomarkers in bladder cancer: present status and perspectives.

Authors:  Wun-Jae Kim; Soongang Park; Yong-June Kim
Journal:  Biomark Insights       Date:  2007-03-27

Review 9.  High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility.

Authors:  Karsten Zieger
Journal:  Mol Oncol       Date:  2007-12-08       Impact factor: 6.603

10.  Targeting Lyn regulates Snail family shuttling and inhibits metastasis.

Authors:  D Thaper; S Vahid; K M Nip; I Moskalev; X Shan; S Frees; M E Roberts; K Ketola; K W Harder; C Gregory-Evans; J L Bishop; A Zoubeidi
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.